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Abstract 
Background: Diabetes mellitus is characterized by chronic vascular inflammation leading to pathological expression 
of the thrombogenic full length (fl) tissue factor (TF) and its isoform alternatively-spliced (as) TF. Blood-borne TF pro-
motes factor (F) Xa generation resulting in a pro-thrombotic state and cardiovascular complications. MicroRNA (miR)s 
impact gene expression on the post-transcriptional level and contribute to vascular homeostasis. Their distinct role in 
the control of the diabetes-related procoagulant state remains poorly understood.
Methods: In a cohort of patients with poorly controlled type 2 diabetes (n = 46) plasma levels of miR-181b were cor-
related with TF pathway activity and markers for vascular inflammation. In vitro, human microvascular endothelial cells 
(HMEC)-1 and human monocytes (THP-1) were transfected with miR-181b or anti-miR-181b and exposed to tumor 
necrosis factor (TNF) α or lipopolysaccharides (LPS). Expression of TF isoforms, vascular adhesion molecule (VCAM) 1 
and nuclear factor (NF) κB nuclear translocation was assessed. Moreover, aortas, spleen, plasma, and bone marrow-
derived macrophage (BMDM)s of mice carrying a deletion of the first miR-181b locus were analyzed with respect to 
TF expression and activity.
Results: In patients with type 2 diabetes, plasma miR-181b negatively correlated with the procoagulant state as 
evidenced by TF protein, TF activity, d-dimer levels as well as markers for vascular inflammation. In HMEC-1, miR-181b 
abrogated TNFα-induced expression of flTF, asTF, and VCAM1. These results were validated using the anti-miR-181b. 
Mechanistically, we confirmed a miR-181b-mediated inhibition of importin-α3 (KPNA4) leading to reduced nuclear 
translocation of the TF transcription factor NFκB. In THP-1, miR-181b reduced both TF isoforms and FXa generation in 
response to LPS due to targeting phosphatase and tensin homolog (PTEN), a principal inducer for TF in monocytes. 
Moreover, in miR-181−/− animals, we found that reduced levels of miR-181b were accompanied by increased TF, 
VCAM1, and KPNA4 expression in aortic tissue as well as increased TF and PTEN expression in spleen. Finally, BMDMs 
of miR-181−/− mice showed increased TF expression and FXa generation upon stimulation with LPS.
Conclusions: miR-181b epigenetically controls the procoagulant state in diabetes. Reduced miR-181b levels contrib-
ute to increased thrombogenicity and may help to identify individuals at particular risk for thrombosis.
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Background
Under diabetic conditions, chronic inflammatory 
signaling in the vasculature sustains endothelial dys-
function, leukocyte infiltration, and a pro-thrombotic 
environment [1, 2].
Tissue factor (TF), the membrane-bound receptor for 
coagulation factor (F) VIIa, is constitutively expressed 
in the perivascular space but under physiological condi-
tions not present in the vasculature or blood [3]. How-
ever, hyperglycemia and pro-inflammatory molecules, 
such as tumor necrosis factor (TNF)α or lipopolysaccha-
rides (LPS), induce the highly thrombogenic full length 
(fl) TF and its less thrombogenic isoform alternatively-
spliced (as) TF [4–6]. Vessel wall-derived flTF mainly 
drives inflammatory signaling via protease-activated 
receptor (PAR)s [7–9], can lead to vascular dysfunction 
under oxidative stress [10], and may contribute to athero-
thrombosis through release in TF-positive procoagulant 
microvesicles (MVs) [11, 12]. In the blood, hematopoietic 
cells, including monocytes and macrophages, and their 
released procoagulant MVs represent the main source of 
TF [13, 14]. When in contact with blood, flTF triggers the 
FVIIa-dependent generation of FXa prompting thrombin 
accumulation and clotting [15]. Particularly, patients with 
poorly controlled diabetes show pathological TF activity 
in the blood accounting for vascular complications [16].
Recently, a critical role of microRNA (miR)s in the 
pathogenesis of cardiovascular diseases (CVD) and 
diabetes-related complications has been demonstrated 
[17–19]. Binding of specific target transcripts by miRs 
leads to mRNA degradation and translational repres-
sion. We have recently shown that miR-126 and miR-
19a target the TF transcript thereby contributing to the 
epigenetic control of vascular inflammation and coagu-
lation [20, 21]. Thus, a procoagulant state in diabetes 
can also be considered a result of a defective miR-medi-
ated control of coagulation factors.
Among endothelial miRs, miR-181b emerged as a 
powerful regulator of vascular homeostasis. Several 
lines of evidence point to implication of miR-181b into 
TF-related thrombogenicity: In endothelial cells (ECs) 
in  vitro, miR-181b targets importin-α3 (KPNA4) and 
thereby reduces nuclear translocation of nuclear factor 
(NF) κB, one of the main transcription factors for vas-
cular TF expression [22]. Moreover, Henao Mejia et  al. 
found that miR-181b targets phosphatase and tensin 
homolog (PTEN), a principal inducer for TF expres-
sion in hematopoietic cells [23]. In monocytes, PTEN 
drives LPS-induced TF expression by negatively regulat-
ing the phosphoinositide 3-kinase (PI3K)/AKT pathway. 
Accordingly, PTEN−/− mice exhibit reduced TF activity 
[24]. In vivo, Lin et al. reported that miR-181b adminis-
tration reduced arterial thrombosis in a photochemical 
injury-model [25], a feature that is also observed in mice 
with reduced vascular TF expression [26, 27]. Finally, 
miR-181b expression is lowered via hyperglycemia and 
pro-inflammatory cytokines that are all known to induce 
TF expression in the vasculature [28].
In the present study, we sought to assess the role of 
miR-181b in the hemostatic balance in advanced diabetes.
In a cohort of patients with poorly controlled type 
2  diabetes, we provide novel evidence that miR-181b 
expression strongly correlates with reduced activation of 
the TF-pathway assessed by TF protein, TF activity, and 
d-dimer levels as well as reduced vascular inflammation. 
In vitro, TF expression and FXa generation was reduced 
by miR-181b in human ECs and monocytes. Using ani-
mals with a deletion of the first miR-181b locus we pro-
vide in  vivo evidence that miR-181b contributes to the 
control of vascular TF activity derived from the endothe-
lium and hematopoietic cells. Our data suggests that the 
epigenetic control by circulating miR-181b is essential 
to ensure the hemostatic balance by reducing inflamma-
tion-driven vascular TF expression.
Research design and methods
Patient study
The study protocol was approved by the local ethics com-
mittee and was performed in accordance to the ethics 
principles in the Declaration of Helsinki. Prior to partici-
pation in the study, each patient gave a written informed 
consent. 46 patients with known diabetes mellitus type 
2 admitted for poor glycemic control at the Diabetes 
Center NRW Bad Oeynhausen, Germany, were included 
in the study. Table 1 shows the patient characteristics.
Animals
Tissues and cells from age- and sex-matched 12–16 weeks 
old miR-181a/b-1−/− mice (B6.Mirc14tm1.1Ankr as already 
described [29], termed “miR-181−/−” throughout this 
article) were kindly provided by Andreas Krueger, Insti-
tute for Molecular Medicine in Frankfurt, Germany). 
These mice carry a constitutive deletion of miR-181a1 
and miR-181b1 and were housed under specific pathogen 
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free conditions in the central animal facility at the Insti-
tute for Molecular Medicine in Frankfurt, Germany.
ELISA experiments and glucose measurements
The protein plasma concentrations were assessed by 
using specific ELISA systems (Table 2) according to the 
Table 1 Patient characteristics
N = 46, shown are either Pearson or Spearman correlation coefficients for normally and not normally distributed continuous variables, respectively. For binary 
variables, a point-biserial correlation was performed. Values presented are mean ± SD, medians [IQR] or percentages
ACE angiotensin-converting enzyme, BMI body mass index, CAD coronary artery disease, CRP c-reactive protein, HbA1c glycated hemoglobin, LDL low-density 




Mean ± SD, median [IQR] 
or percentage
Correlation coefficient vs. miR-
181b
p-value
Age (years) 65.6 ± 9.3 − 0.053 0.722
Female gender (%) 26.0 0.011 0.941
BMI (kg/m2) 30.6 [27.75–35.25] 0.203 0.175
Minimal fasting blood glucose (mg/dL) 93.0 [75.75–128.3] − 0.105 0.485
Maximal fasting blood glucose (mg/dL) 197.5 [140.5–238.8] 0.146 0.332
Average fasting blood glucose (mg/dL) 139.1 [117.8–166.5] − 0.012 0.934
HbA1c (%) 8.39 ± 1.61 0.2895 0.051
HbA1c (mmol/mol) 68.1 ± 17.7 0.2895 0.051
CRP (mg/dL) 0.40 [0.14–0.64] − 0.051 0.733
Leukocytes (N/nL) 7.4 [6.37–9.12] − 0.295 0.045*
Neutrophils (%) 59.4 [52.03–66.65] − 0.318 0.031*
Monocytes (%) 6.83 ± 2.29 0.028 0.850
d-Dimers (ng/mL) 377.8 [247.4–523.5] − 0.343 0.019*
Hemoglobin (g/dL) 14.0 ± 1.2 − 0.089 0.555
Homocysteine (µmol/L) 12.5 [10.95–17.08] 0.071 0.637
thrombocytes (N/nL) 211.9 ± 51.7 − 0.226 0.130
Triglycerides (mg/dL) 186 [110.3–271.0] 0.222 0.136
LDL cholesterol (mg/dL) 113 [88–135] 0.043 0.796
miR-181b-5p 0.169 [0.014–0.470] 1
hypertension (%) 100
CAD (%) 41.3 − 0.177 0.236
PAD (%) 26.0 − 0.096 0.521
carotid stenosis (%) 8.6 − 0.133 0.375
history of stroke (%) 10.8 − 0.249 0.094
History of myocardial infarction (%) 15.2 − 0.006 0.964
Medication
 Insulin (%) 69.5 − 0.135 0.370
 Metformin (%) 50.0 0.462 < 0.001*
 Sulfonylurea (%) 17.3 − 0.146 0.330
 Statin (%) 50.0 − 0.040 0.787
 Diuretics (%) 60.8 0.164 0.274
 ACE inhibitor (%) 47.8 0.114 0.447
 Angiotensin receptor blocker (%) 28.2 0.194 0.194
 Aldosterone antagonist (%) 8.6 − 0.017 0.908
 Calcium antagonist (%) 17.3 − 0.177 0.239
 Nitrate vasodilators (%) 13.0 − 0.034 0.822
 Acetylsalicylic acid (%) 58.7 − 0.021 0.886
 Beta-blocker (%) 50.0 0.194 0.194
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manufacturer’s instructions. Fasting blood glucose lev-
els in patients were measured by a standardized labora-
tory test, while further glucose levels during the day were 
obtained by a finger-prick test from capillary blood.
TF activity
The measurement of TF activity was performed as 
described before [2]. The recombinant FVIIa was kindly 
provided by Novo Nordisk.
Cell culture
HMEC from ATCC were maintained in MCBD 131 
medium (Gibco) supplemented with 10% FBS (Gibco), 
100  U/mL penicillin/streptomycin (PAA), 2  mM l-glu-
tamin (PAA), and 0.05  mg/mL hydrocortison. HMEC 
were used for experiments until the 13th passage. THP-1 
cells from ATCC were grown in RPMI 1640 medium 
(Gibco) supplemented with 10% FBS and 1% penicillin/
streptomycin.
Transfection and stimulation experiments
HMEC-1 and THP-1 were transfected with 200 nM of the 
oligonucleotides listed in Table  2 using the siRNA trans-
fection reagent interferin (VWR) according to manufac-
turer’s protocol. 24 h post transfection cells were starved 
in MCBD 131 medium (Gibco) for 2 h and then stimulated 
with 10  ng/mL TNFα for 2  h for gene expression analy-
sis and 6 h or 24 h for TF or VCAM1 protein expression, 
respectively. THP-1 cells were stimulated with LPS (10 µg/
mL, Sigma) for 2 h for mRNA expression analysis and 6 h 
for assessment of TF activity. For siRNA-mediated knock 
down experiments THP-1 were transfected for 48 h.
Real time PCR
For real-time PCR, total mRNA was isolated from cul-
tured cells and murine tissue with peqGOLD Trifast 
(Peqlab) and for patient blood plasma using the mirVana 
Paris Kit (Life Technologies). Gene expression was deter-
mined using  GoTaq® Probe qPCR Master Mix (Promega) 
with FAM-tagged  TaqMan® gene expression assays (life 
Technologies) or via SYBR Green assays using  SYBR® 
Select Master Mix (applied Biosystems) with specific 
primers (Table  2). Relative gene expression was deter-
mined via the comparative C(t) (ΔΔCt) method with 
GAPDH or 18S ribosomal RNA as endogenous control 
for mRNA and U6 snRNA for miR.
Western blot
Western blots were performed as described before [3]. 
Nuclear and cellular lysates were isolated using the NE-
PER™ Nuclear and Cytoplasmic Extraction Reagents 
(Thermo Fisher Scientific) following the manufacturer’s 
instructions. Antibodies used are listed in Table  2. The 
western blots have been performed ≥ 3 times.
Immunofluorescence
For protein staining aortas and spleen were embedded in 
Tissue-Tek and immunofluorescence was performed with 
specific antibodies and probes (Table 2).
Whole blood microvesicle-associated FXa generation
TF activity of whole blood mouse MVs was assessed as 
previously described [4]. Briefly, whole blood was drawn 
Table 2 Material
Application Materials
ELISA TF ELISA kit (Sekisui), d-dimer ELISA kit (Diagnostica Stago), and TAT ELISA kit (Siemens Healthcare)
Transfection Negative control mimic (Dharmacon), 200 nM miR-181b mimic (hsa-miR-181b-5p, HMI0270, Sigma), 200 nM anti-miR-181b (anti-hsa-
miR-181b-5p, HSTUD0270, Sigma), 200 nM inhibitor control (Dharmacon), siRNA against PTEN (L-003023-00-0005), (Dharmacon) or 
a control siRNA (Dharmacon)
Taqman PCR miR-181b-5p (001098), mouse asTF (custom-made), mouse flTF (Mm00438856_m1), human VCAM1 (Hs01003372), mouse VCAM1 
(Mm00449197_m1), human PTEN (Hs01628827_s1), mouse PTEN (Mm00477208_m1), mouse KPNA4 (Mm00434725_m1), human 
GAPDH (Hs99999905_m1), mouse GAPDH (Mm99999915_g1), U6snRNA (001973), and self-designed FAM-tagged  TaqMan® gene 
expression assays for human flTF and asTF (for details see [44])
SYBR Green PCR Human GAPDH (forward 5′-AGC CAC ATC GCT CAG ACA C-3′, reverse 5′-GCC CAA TAC GAC CAA ATC C-3′), human KPNA4 Forward 5′-CAG 
GAG ATT CTT CCA GCC CTT TGT GT-3′, Reverse 5′-ATT ACC ATC TGT ATT TGT TCA TTG CCA GCA TC-3′)
Western blot Human flTF (Sekisui diagnostics, 4501, goat IgG), human asTF (monoclonal rabbit, kindly provided by Prof. Vladimir Bogdanov, Uni-
versity of Cincinnati), human VCAM1 (Cell signaling, 13662S, rabbit IgG), human-KPNA4 (Abcam, ab6039, goat IgG), human PTEN 
(Cell signaling, 9559, rabbit IgG), human p-NFκB (Cell signaling, 3033, rabbit IgG), human NFκB (Santa Cruz, sc-109, rabbit IgG), 
human histone H3 (Cell signaling, 9715, rabbit), mouse and human GAPDH (Calbiochem, CB1001, mouse IgG), mouse TF (Sekisui 
diagnostics, 4515, rabbit IgG), mouse VCAM1 (Cell signaling, 39036, rabbit IgG)
IFA Mouse TF (Sekisui diagnostics, 4515, rabbit IgG), mouse VCAM1 (Cell signalling, 39036, rabbit IgG), Goat anti Rabbit (Dianova), DAPI 
(Invitrogen), F-actin probe, Alexa Fluor 647 Phalloidin (Thermo Fisher, A12379)
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by vena cava puncture and 10% citrate added. The cell 
counts for normalization of the TF activity to the mono-
cyte count was done with a Vetscan automated cell 
counter. The whole blood was stimulated with 10 µg/mL 
LPS for 4 h to induce MV release and centrifuged 2 × at 
3000g. The plasma was centrifuged again for 40 min, 4 °C, 
at 18000g to isolate MVs. MV TF activity was determined 
by adding 2  nM mouse recombinant FVIIa (kindly pro-
vided by H. Ostergaard, Novo Nordisk) and 50  nM FX 
(Haematologic Technologies) to resuspended MVs in 
HBS (10 mM Hepes, pH 7.4, 137 mM NaCl, 5.3 mM KCl, 
1.5 mM CaCl2). FXa was measured by using the chromo-
genic substrate Spectrozyme FXa (Sekisui Diagnostics).
Culture of bone marrow-derived macrophages (BMDMs)
BMDMs were in vitro–differentiated as described before 
[5]. Briefly, isolated bone marrow cells were cultivated in 
DMEM supplemented with 20% L cell medium, 10% FCS, 
1 mM l-glutamine, penicillin, and streptomycin. On day 
7 macrophages were seeded at a density of 1 × 106 per 
well. On the next day, macrophages were stimulated with 
1 µg/mL LPS (Enzo Life Sciences) for 4 h. The cells were 
then lysed for RNA analysis, western blot or measure-
ment of FXa generation as described above.
Statistical analysis
The statistical analyses were performed using the soft-
ware GraphPad Prism 7. Correlation of patient char-
acteristics were performed via Pearson correlation for 
normally distributed values or Spearman correlation in 
case of not normal distribution. For binary variables, a 
point-biserial correlation was performed. Differences 
between 2 groups were examined using a Mann–Whit-
ney test or student’s t test (2-tailed). For comparisons of 
1 parameter between more than two related groups the 
one-way ANOVA test with Dunn’s multiple comparison 
as post hoc test was used. For data sets with 4 groups and 
2 variables a 2-way ANOVA test with Sidak’s multiple 
comparison post hoc test was performed. Data are rep-
resented as mean ± SEM. p-values < 0.05 are considered 
statistically significant.
Results
We hypothesized an association of miR-181b with vas-
cular TF expression in the setting of diabetes. Therefore, 
46 patients with type 2 diabetes admitted to a diabetes 
center because of insufficient glycemic control (mean 
HbA1c 8.39 ± 1.61% or 68.1 ± 17.7  mmol/mol) were 
enrolled in the study. Compared to healthy control sub-
jects with normal TF protein levels in the plasma (median 
TF protein 102.2 pg/mL [Q1 75.8, Q3 136.1], Additional 
file  1: Table  S1), the enrolled diabetics presented a pro-
thrombotic state (median TF protein 291.3  pg/mL [Q1 
165.3, Q3 373.9] and median TF activity 496.8 U/mL [Q1 
293.4, Q3 727.7]). No association of miR-181b with blood 
glucose levels was observed. However, circulating miR-
181b showed a strong negative correlation with TF pro-
tein (Fig. 1a, r = − 0.48, p < 0.001) and TF activity (Fig. 1b, 
r = − 0.82, p < 0.0001). Moreover, miR-181b correlated 
with reduced levels of d-dimers    of the TF pathway 
(r = − 0.34, p < 0.05, Table 1). Furthermore, miR-181b was 
related to a lower grade of inflammation as evidenced 
by a negative correlation with fibrinogen and leukocyte 
count (Fig. 1c, d). In line with this, miR-181b was posi-
tively associated with metformin treatment that is known 
to reduce vascular inflammation (r = 0.462, p < 0.001, 
Table 1). Plasma miR-181b also correlated with the anti-
thrombotic miR-126 and miR-19a (r = 0.79, p < 0.0001 
and r = 0.73, p < 0.0001, respectively, Fig. 1e, f ).
In human microvascular endothelial cells (HMEC)-1, 
hyperglycemia and the pro-inflammatory cytokine TNFα 
reduced miR-181b levels, whereas it induced both TF 
isoforms and the NFκB-dependent vascular cell adhesion 
molecule (VCAM) 1 (Additional file  2: Figure  S1A–H). 
We analyzed the effect of miR-181b on the inflammation-
induced TF expression in ECs. HMEC-1 were therefore 
transfected with miR-181b or anti-miR-181b as well 
as the appropriate controls and stimulated with 10  ng/
mL TNFα. In miR-181b transfected cells, we observed a 
reduction of both TF isoforms on the mRNA and pro-
tein level in cells stimulated with TNFα for 2 h and 6 h, 
respectively, whereas anti-miR-181b increased asTF and 
flTF expression under inflammatory conditions (Fig. 2a–
e). We confirmed that miR-181b reduces and anti-miR-
181b induces VCAM1 in HMEC-1 (Fig.  2f–h). As the 
mechanism for inhibition of TNFα-induced TF expres-
sion we found a downregulation of KPNA4 in HMEC-1 
mRNA and protein (Additional file  3: Figure  S2A, B) 
consistent with a decrease in NFκB nuclear translocation 
exhibited by miR-181b (Fig. 2i).
To assess whether miR-181b also reduces TF expres-
sion in human monocytes, the main source of TF activ-
ity in the blood, THP-1 cells were transfected with 
miR-181b and then stimulated with LPS to induce TF 
expression. Due to the low endogenous expression level 
of miR-181b in monocytes, a gain of function approach 
was used. We found that miR-181b reduced mRNA lev-
els of both TF isoforms (Fig. 3a, b) and FXa generation 
(Fig. 3c) following LPS treatment of THP-1. In contrast 
to ECs, LPS-induced NFκB was not restricted to the 
cytoplasmatic compartment in THP-1 (Fig.  3d, upper 
panel) nor were KPNA4 mRNA levels reduced by miR-
181b (Fig.  3e). However, miR-181b led to a marked 
reduction in NFκB phosphorylation and subsequent 
nuclear translocation (Fig.  3d, both panels) suggesting 
an upstream effect on NFκB activation. We suspected 
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that control of PTEN expression may contribute to the 
miR-181b-mediated reduction of TF activity in mono-
cytes. Indeed, PTEN expression was reduced in THP-1 
cells transfected with miR-181b (Fig.  3f, g). siRNA-
mediated knock down of PTEN reduced LPS-induced 
expression of flTF and asTF in THP-1 and phenocopied 
the miR-181b effect (Fig. 3h–j).
To assess the significance of our experimental findings 
in vivo, animals carrying a deletion of the first miR-181b 
locus (as well as miR-181a-1; B6.Mirc14tm1.1Ankr, here 
referred to as miR-181−/− mice) with reduced vascu-
lar miR-181b expression were analyzed (Fig.  4a). While 
no change for asTF mRNA was observed, we found an 
increase in flTF mRNA and protein expression in miR-
181−/− aortas as compared to wt mice, (Fig.  4b–d). 
Immunofluorescence using a murine TF-specific anti-
body revealed that the rise in TF protein in miR-181−/− 
aortas originated from the endothelial layer (Fig.  4e, 
upper panel). Moreover, expression of KPNA4 (Fig. 4f ) as 
well as VCAM1 mRNA and protein (Fig.  4g, h, e lower 
panel) were increased in aortas of miR-181−/− animals. 
To assess TF expression in hematopoietic cells, the spleen 
of miR-181−/− mice was analyzed. Here, miR-181b was 
reduced (Additional file 5: Figure S4a) while both TF iso-
forms and PTEN mRNA were increased as compared to 
wt animals (Fig. 4i–m).
To investigate the blood procoagulant activity of miR-
181b−/− animals, whole blood was stimulated with LPS 
and the FXa generation of MVs assessed. We did not 
observe a difference in MV-associated FXa generation 
between blood of wt and ko animals (Additional file  5: 
Figure  S4B). In line, no differences in plasma thrombin 
anti-thrombin complexes was seen between wt and ko 
animals (Additional file  5: Figure  S4C). However, iso-
lated bone marrow-derived macrophages (BMDM), that 
have been shown to contribute to blood thrombogenic-
ity, showed a strong reduction in miR-181b expression in 
the miR-181−/− animals (Fig.  5a) and exhibited higher 
levels of asTF and flTF mRNA (Fig. 5b, c) as well as more 
TF protein and FXa generation (Fig. 4d, e) in response to 
LPS than wt cells.
Discussion
Here, we report that miR-181b controls thrombogenicity 
in the vasculature and correlates with reduced circulating 
TF and vascular inflammation in patients with diabetes. 
Using human ECs and monocytic cells, we demonstrate 
that miR-181b reduces the inflammation-induced vascu-
lar TF expression and FXa generation. In a murine miR-
181 ko system, we provide in  vivo evidence that loss of 
miR-181b promotes endothelial and hematopoietic TF 
expression. Our work demonstrates that miR-181b is a 
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Fig. 1 Plasma miR-181b correlates with reduced tissue factor activity and inflammation in diabetes. Plasma of patients with diabetes was analyzed 
with respect to miR-181b expression. Circulating miR-181b negatively correlated with TF protein (a) as well as TF activity (FXa generation) (b). 
Moreover, miR-181b expression was related to lower levels of the pro-inflammatory fibrinogen (c) and lower leukocyte counts (d). We also observed 
a correlation of miR-181b with the TF-specific miR-126 (e) and miR-19a (f). n = 46. Upon normality testing a Spearman or Pearson correlation was 
performed, r-values and p-values are indicated
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pivotal regulator of thrombogenicity and contributes to 
vascular homeostasis in the presence of poorly controlled 
diabetes.
Low miR-181b: association with a pro-thrombotic 
and pro-inflammatory state
In the healthy vasculature, circulating miRs epigeneti-
cally control pro-inflammatory transcription factors and 
their gene products to preserve vascular homeostasis [3, 
30–32]. However, in a diabetic environment this protec-
tive miR transcriptome is disrupted [33]. In particular, 
diabetes-related loss of TF-specific miRs, such as miR-
126 or miR-223 contributes to vascular inflammation and 
a pro-thrombotic state [33, 34].
Here we show that miR-181b, a key regulator for 
endothelial function, beta cell function, peripheral 
insulin sensitivity, and NFκB signaling [22, 28, 35], par-
ticipates in the control of vascular TF activity in dia-
betes. In poorly controlled diabetics, miR-181b was 
associated with reduced activation of the TF pathway, 
lower leukocyte count, and fibrinogen, which both con-
stitute independent risk factors for cardiovascular mor-
tality among patients with diabetes [36].
In contrast to markers of inflammation, miR-181b lev-
els did not correlate with blood glucose or HbA1c in our 
cohort. Although we and Sun et al. [28] found that miR-
181b expression in HMEC-1 and human umbilical vein 
endothelial cells (HUVEC) is reduced by high glucose 
concentrations, Yang et al. [37] reported activation of the 
miR-181a/b-specific transcription factor signal trans-
ducer and activator of transcription (STAT) 3 in HUVEC 
treated with sera from diabetics pointing to a more com-
plex regulation of miR-181b expression in humans. This 
may explain why the miR-181b expression in our healthy 
controls did not differ from those in poorly controlled 
diabetes (Additional file  6: Figure  S5A). In contrast, 
miR-126 that has been shown to be reduced in diabetes 
in the population-based Bruneck cohort, was signifi-
cantly lower in our diabetes cohort compared to healthy 
controls confirming the quality of our measurements 
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Fig. 2 miR-181b reduces the inflammation-induced expression of tissue factor in HMEC-1. HMEC-1 were transfected with a control mimic or 
miR-181b as well as a negative control inhibitor or anti-miR-181b. The cells were left untreated or stimulated with TNFα for 2 h for mRNA analysis 
of asTF (a, b) and flTF (c, d) or 6 h for TF protein (e). VCAM1 mRNA expression (f, g) and protein (h) in HMEC-1 transfected with miR-181b or 
anti-miR-181b following TNFα for 2 h and 6 h, respectively. Nuclear extracts (i, left panel) and cytoplasmatic extracts (i, right panel) of HMEC 
transfected with miR-181b or a control mimic at rest or stimulated with TNFα for 1 h subjected to western blot analysis using antibodies against 
NFκB, histone H3 (H3), or β-actin. n ≥ 3, groups were compared by 2-way ANOVA test with global p-values for treatment with TNFα and Sidak’s 
multiple comparison post hoc test
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conditions beyond glycemia impact miR-181b expression 
resulting in differential expression levels among diabet-
ics. Although we cannot rule out an impact of co morbid-
ities and anti-diabetic drugs on miR-181b expression in 
our cohort, it seems likely that chronic inflammation in 
an advanced state of the disease is a more relevant factor 
than blood glucose for miR-181b suppression. In accord-
ance, we found co expression of miR-181b with miR-126 
and miR-19a that are both reduced by inflammatory 
cytokines [20, 21].
TF in the endothelium is reduced by miR-181b 
under inflammatory conditions
Our data indicates that miR-181b restrains NFκB-
depending TF expression in human and murine ECs 
via targeting of KPNA4. The direct contribution of 
vessel wall-derived TF to thrombosis has been a matter of 
debate [4]. Yet, through allosteric activation of FVIIa and/
or FXa generation, TF promotes pro-inflammatory PAR 
signaling leading to sustained vascular dysfunction. Con-
sequently, an EC-specific deletion of TF reduced circulat-
ing inflammatory cytokines [38]. Recently, clinical trials 
provided strong evidence that the TF/VIIa/Xa pathway 
contributes to vascular complications and pharmaco-
logical blockage of FXa at low doses prevented ischemic 
CVD endpoints [39]. However, inhibition of vascular TF 
and PARs are challenged by bleeding issues due to their 
role in hemostasis and platelet function, respectively [40]. 
Our study identifies miR-181b as a potent regulator for 
pathological TF-induced vascular inflammation. Further 
clinical research needs to assess the therapeutic potential 





























































































































































































































Fig. 3 miR-181b inhibits LPS-induced tissue factor activity in THP-1. THP-1 cells were transfected with miR-181b and stimulated with LPS for 2 h to 
assess asTF and flTF mRNA (a, b) or 6 h for TF activity (c). THP-1 were transfected with a control mimic or miR-181b and then stimulated with LPS 
for 1 h. Cytoplasmatic extracts (d, upper panel) and nuclear extracts (d, lower panel) were then subjected to western blot analysis using antibodies 
against phospho-NFκB (phospho p65), NFκB (p65), histone H3 (H3), or GAPDH (bands show samples with equal loading of the same gel. The 
original blots can be found in Additional file 3: Figure S3). KPNA4 mRNA (e), PTEN mRNA (f) and protein (g) in THP-1 transfected with a control miR 
or miR-181b. THP-1 were transfected with a control siRNA or siRNA against PTEN. PTEN knock down was confirmed via quantification of PTEN mRNA 
(h) and led to reduced mRNA levels of flTF (i) and asTF (j). n ≥ 3, groups were compared by 2-way ANOVA test with global p-values for treatment 
with LPS and Sidak’s multiple comparison post hoc test (a, b) or student’s t-test
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Endothelial miR-181b governs hematopoietic TF activity 
via PTEN
In the vasculature, hematopoietic cells represent the 
main pool of circulating TF and contribute to thrombosis 
[13, 26]. Here, we show that miR-181b reduces TF activ-
ity in human monocytes through control of PTEN.
The strong negative correlation of circulating miR-181b 
with plasma TF activity in our patient cohort suggests 
that the mostly endothelial-derived miR-181b impacts 
monocytic TF production in humans. Recent studies 
reported that ECs can modulate the phenotype of mono-
cytes via release of endothelial MVs. Njock et  al. [41] 
showed that miR-181b along with other anti-inflamma-
tory miRs is enriched in EC-derived MVs. Treatment of 
recipient THP-1 with EC-MVs or with miR-181b mimics 
repressed LPS-induced inflammatory gene expression 
in monocytes. These data along with our study highlight 
that endothelial miR-181b exerts anti-thrombotic prop-
erties beyond the vasculature by also modulating the 
thrombotic phenotype of monocytic cells and support 
the hypothesis that the endothelium at least indirectly 
participates in the regulation of plasma TF activity.
In contrast to ECs, miR-181b did not alter NFκB 
nuclear translocation in human monocytes. Different 
host cell factors that preclude down regulation of KPNA4 
may explain this observation. However, we are the first to 
show that miR-181b controls upstream NFκB activation 
in monocytes via targeting PTEN. The PI3K/AKT path-
way was previously shown to negatively regulate LPS-
induced TF transcription in human monocytes through 
downstream control of NFκB along with the TF-specific 
transcription factors activator protein (AP)-1 and early 
growth response (EGR)-1 [42]. Consequently, targeting 
of the PI3K/AKT negative regulator PTEN by miR-181b 
reduces LPS-induced TF expression and possibly other 
inflammatory factors.
Differences of miR-181b’s effect in the murine system
In the murine system, miR-181b deficiency failed to alter 
monocyte-derived MV-TF activity but increased TF 
expression in spleen and BMDM.
In line with previous reports showing that miR-181b 
does not alter NFκB reporter activity of mouse periph-
eral blood mononuclear cell (PBMC)s [32], we did not 
observe changes in MV-associated monocytic TF activ-
ity or TAT levels. As suggested by Sun et al., differential 
expression of importin isoforms in mouse monocytes 
may be the underlying cause. However, our study shows 
a b c d e
f g h
i j k l
m
Fig. 4 Loss of miR-181b induces tissue factor and VCAM1 expression in vivo. Aortas and spleen of miR-181−/− mice were analyzed with respect to 
mRNA and protein expression. miR-181b (a), asTF mRNA (b), flTF mRNA (c), murine (mu) TF protein (d) and immunofluorescence (IF) images using 
an anti-mouse (mu) TF antibody (red), DAPI (blue), and a F-actin probe (green) (e upper panel) in aortic segments. KPNA4 mRNA (f), VCAM1 mRNA 
(g), VCAM1 protein (h), and IF images using a mouse VCAM1-specific antibody (red) (e lower panel) in aortic tissue. Expression of asTF mRNA (i), flTF 
mRNA (j), PTEN mRNA (k), muTF protein (l), and IF for muTF (red)(M) in spleen of wt and miR-181−/− animals. n = 4–6 animals per group, compared 
by Mann–Whitney or student’s t-test
Page 10 of 12Witkowski et al. Cardiovasc Diabetol           (2020) 19:20 
that miR-181b reduces hematopoietic TF production in 
murine BMDM. Macrophages not only produce TF-pos-
itive thromboinflammatory MVs [14] but also account 
for TF accumulation in atherosclerotic plaques [43]. 
Reduced TF expression in macrophages may contribute 
to the observation that miR-181b overexpression in Apo 
E−/− mice protects from atherosclerosis [32].
Limitations
miR expression in patient plasma samples was normal-
ized to U6 which can be altered in some diseases. How-
ever, this has not been reported in patients with diabetes 
and our expression profiles in both cohorts are in accord-
ance with previously published data [34]. Moreover, the 
miR-181−/− mouse model analyzed here carries a dele-
tion of miR-181b-1 and the adjacent miR-181a-1 as well. 
Due to transcriptional co-regulation and high sequence 
similarities both miRs share largely the same func-
tions. Accordingly, some of our findings might also be 
explained by loss of miR-181a.
Conclusions
Our work shows that circulating miR-181b contributes 
to the control of diabetes-related thrombogenicity and 
vascular inflammation (Fig. 6). Low miR-181b expression 
may identify patients at particular risk for thromboem-
bolic complications. Vice versa, posttranscriptional con-
trol of vascular TF expression by miR-181b represents 
a potential avenue to improve endothelial dysfunction 
and thrombosis risk without facing bleeding issues as 
observed by direct inhibition of inflammatory coagu-













































































































Fig. 5 miR-181b deletion in bone marrow-derived macrophages 
leads to increased TF expression and FXa generation upon 
inflammation. Bone marrow-derived macrophages (BMDM) were 
isolated from wt mice or miR-181−/− animals and cultured. The cells 
were either left untreated or stimulated with 1 µg/mL LPS for 4 h. 
Next, the miR-181b expression (a), asTF mRNA (b), flTF mRNA (c), FXa 
generation (d), and muTF protein (e) were measured. n = 3–6 animals 
per group, groups were compared by 2-way ANOVA test with global 





Fig. 6 Role of miR-181b in vascular homeostasis
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explore the prognostic value of miR-181b for prediction 
of major adverse cardiac events.
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